{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:23:43Z","timestamp":1771860223530,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,11]]},"DOI":"10.7759\/cureus.41697","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T13:48:37Z","timestamp":1689083317000},"source":"Crossref","is-referenced-by-count":5,"title":["The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Marcelo","family":"Salazar-Barragan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R","family":"Taub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo J","year":"2022","unstructured":"Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022, 21:456-462. 10.1016\/j.jcf.2022.01.009","journal-title":"J Cyst Fibros"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/AGG.S53768","article-title":"Cystic fibrosis gene mutations: evaluation and assessment of disease severity","volume":"4","author":"Valli\u00e8res E","year":"2014","unstructured":"Valli\u00e8res E, Elborn JS. Cystic fibrosis gene mutations: evaluation and assessment of disease severity. Adv Genomics Genet. 2014, 4:161-172. 10.2147\/AGG.S53768","journal-title":"Adv Genomics Genet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2013.01.006","article-title":"CFTR2: how will it help care?","volume":"14","author":"Castellani C","year":"2013","unstructured":"Castellani C. CFTR2: how will it help care?. Paediatr Respir Rev. 2013, 14:2-5. 10.1016\/j.prrv.2013.01.006","journal-title":"Paediatr Respir Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco M","year":"2016","unstructured":"Lopes-Pacheco M. CFTR modulators: shedding light on precision medicine for cystic fibrosis. Front Pharmacol. 2016, 7:275. 10.3389\/fphar.2016.00275","journal-title":"Front Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/membranes11110804","article-title":"The distribution and role of the CFTR protein in the intracellular compartments","volume":"11","author":"Lukasiak A","year":"2021","unstructured":"Lukasiak A, Zajac M. The distribution and role of the CFTR protein in the intracellular compartments. Membranes (Basel). 2021, 11:10.3390\/membranes11110804","journal-title":"Membranes (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations\u2014correlation with incidence data and application to screening","volume":"19","author":"Bobadilla JL","year":"2002","unstructured":"Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations\u2014correlation with incidence data and application to screening. Hum Mutat. 2002, 19:575-606. 10.1002\/humu.10041","journal-title":"Hum Mutat"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1179551419851770","article-title":"Cystic fibrosis-related diabetes: pathophysiology and therapeutic challenges","volume":"12","author":"Kelsey R","year":"2019","unstructured":"Kelsey R, Manderson Koivula FN, McClenaghan NH, Kelly C. Cystic fibrosis-related diabetes: pathophysiology and therapeutic challenges. Clin Med Insights Endocrinol Diabetes. 2019, 12:10.1177\/1179551419851770","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2021.100290","article-title":"Cystic fibrosis-related diabetes: prevalence, screening, and diagnosis","volume":"27","author":"Khare S","year":"2022","unstructured":"Khare S, Desimone M, Kasim N, Chan CL. Cystic fibrosis-related diabetes: prevalence, screening, and diagnosis. J Clin Transl Endocrinol. 2022, 27:100290. 10.1016\/j.jcte.2021.100290","journal-title":"J Clin Transl Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00020","article-title":"Cystic fibrosis-related diabetes","volume":"9","author":"Kayani K","year":"2018","unstructured":"Kayani K, Mohammed R, Mohiaddin H. Cystic fibrosis-related diabetes. Front Endocrinol (Lausanne). 2018, 9:20. 10.3389\/fendo.2018.00020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis-related diabetes","volume":"107","author":"Moheet A","year":"2022","unstructured":"Moheet A, Moran A. New concepts in the pathogenesis of cystic fibrosis-related diabetes. J Clin Endocrinol Metab. 2022, 107:1503-1509. 10.1210\/clinem\/dgac020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.02.008","article-title":"Update on cystic fibrosis-related diabetes","volume":"12","author":"Kelly A","year":"2013","unstructured":"Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013, 12:318-331. 10.1016\/j.jcf.2013.02.008","journal-title":"J Cyst Fibros"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis-related diabetes in Europe: prevalence, risk factors and outcome","volume":"19","author":"Olesen HV","year":"2020","unstructured":"Olesen HV, Drevinek P, Gulmans VA, et al.. Cystic fibrosis-related diabetes in Europe: prevalence, risk factors and outcome. J Cyst Fibros. 2020, 19:321-327. 10.1016\/j.jcf.2019.10.009","journal-title":"J Cyst Fibros"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009761","article-title":"Cystic fibrosis transmembrane regulator correctors and potentiators","volume":"3","author":"Rowe SM","year":"2013","unstructured":"Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med. 2013, 3:a009761. 10.1101\/cshperspect.a009761","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2014\/6486.5158","article-title":"Ivacaftor: a novel mutation modulating drug","volume":"8","author":"Kapoor H","year":"2014","unstructured":"Kapoor H, Koolwal A, Singh A. Ivacaftor: a novel mutation modulating drug. J Clin Diagn Res. 2014, 8:SE01-SE05. 10.7860\/JCDR\/2014\/6486.5158","journal-title":"J Clin Diagn Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000627","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis","volume":"30","author":"Burgener EB","year":"2018","unstructured":"Burgener EB, Moss RB. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Curr Opin Pediatr. 2018, 30:372-377. 10.1097\/MOP.0000000000000627","journal-title":"Curr Opin Pediatr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2021.100286","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh L","year":"2022","unstructured":"Merjaneh L, Hasan S, Kasim N, Ode KL. The role of modulators in cystic fibrosis related diabetes. J Clin Transl Endocrinol. 2022, 27:100286. 10.1016\/j.jcte.2021.100286","journal-title":"J Clin Transl Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2022.100301","article-title":"The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetes","volume":"29","author":"Hasan S","year":"2022","unstructured":"Hasan S, Khan MS, Lansang MC. The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetes. J Clin Transl Endocrinol. 2022, 29:100301. 10.1016\/j.jcte.2022.100301","journal-title":"J Clin Transl Endocrinol"},{"key":"ref18","unstructured":"Kaftrio | European Medicines Agency . (2020). Accessed. June 14, 2023: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio.."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29359","article-title":"Newly discovered cutting-edge triple combination cystic fibrosis therapy: a systematic review","volume":"14","author":"Dawood SN","year":"2022","unstructured":"Dawood SN, Rabih AM, Niaj A, et al.. Newly discovered cutting-edge triple combination cystic fibrosis therapy: a systematic review. Cureus. 2022, 14:e29359. 10.7759\/cureus.29359","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16144","article-title":"A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher A","year":"2021","unstructured":"Zaher A, ElSaygh J, Elsori D, ElSaygh H, Sanni A. A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus. 2021, 13:e16144. 10.7759\/cureus.16144","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Benninger LA","year":"2021","unstructured":"Benninger LA, Trillo C, Lascano J. CFTR modulator use in post lung transplant recipients. J Heart Lung Transplant. 2021, 40:1498-1501. 10.1016\/j.healun.2021.08.009","journal-title":"J Heart Lung Transplant"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor-tezacaftor-ivacaftor improves exercise capacity in adolescents with cystic fibrosis","volume":"57","author":"Causer AJ","year":"2022","unstructured":"Causer AJ, Shute JK, Cummings MH, et al.. Elexacaftor-tezacaftor-ivacaftor improves exercise capacity in adolescents with cystic fibrosis. Pediatr Pulmonol. 2022, 57:2652-2658. 10.1002\/ppul.26078","journal-title":"Pediatr Pulmonol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2022.100311","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan CL","year":"2022","unstructured":"Chan CL, Granados A, Moheet A, et al.. Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis. J Clin Transl Endocrinol. 2022, 30:100311. 10.1016\/j.jcte.2022.100311","journal-title":"J Clin Transl Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2022.100307","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow H","year":"2022","unstructured":"Crow H, Bengtson C, Shi X, Graves L 3rd, Anabtawi A. CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy. J Clin Transl Endocrinol. 2022, 30:100307. 10.1016\/j.jcte.2022.100307","journal-title":"J Clin Transl Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten I","year":"2022","unstructured":"Korten I, Kieninger E, Krueger L, et al.. Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study. Front Pediatr. 2022, 10:852551. 10.3389\/fped.2022.852551","journal-title":"Front Pediatr"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen MC","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022, 21:265-271. 10.1016\/j.jcf.2021.11.012","journal-title":"J Cyst Fibros"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona C","year":"2022","unstructured":"Piona C, Mozzillo E, Tosco A, et al.. Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis. J Clin Med. 2022, 11:10.3390\/jcm11144149","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos KJ","year":"2022","unstructured":"Ramos KJ, Guimbellot JS, Valapour M, et al.. Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients. J Cyst Fibros. 2022, 21:745-752. 10.1016\/j.jcf.2022.04.009","journal-title":"J Cyst Fibros"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully KJ","year":"2022","unstructured":"Scully KJ, Marchetti P, Sawicki GS, et al.. The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2022, 21:258-263. 10.1016\/j.jcf.2021.09.001","journal-title":"J Cyst Fibros"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2022.101775","article-title":"Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis","volume":"40","author":"Stekolchik E","year":"2022","unstructured":"Stekolchik E, Saul D, Chidekel A. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis. Respir Med Case Rep. 2022, 40:101775. 10.1016\/j.rmcr.2022.101775","journal-title":"Respir Med Case Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados A","year":"2023","unstructured":"Granados A, Chan CL, Moheet A, Vigers T, Arbel\u00e1ez AM, Larson Ode K. The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis. Pediatr Pulmonol. 2023, 58:1805-1811. 10.1002\/ppul.26388","journal-title":"Pediatr Pulmonol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1159\/000530571","article-title":"Improvements in glucose regulation in children and young people with cystic fibrosis-related diabetes following initiation of elexacaftor\/tezacaftor\/ivacaftor","author":"Park J","year":"2023","unstructured":"Park J, Walsh A, Kerr S, et al.. Improvements in glucose regulation in children and young people with cystic fibrosis-related diabetes following initiation of elexacaftor\/tezacaftor\/ivacaftor. Horm Res Paediatr. 2023, 10.1159\/000530571","journal-title":"Horm Res Paediatr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","author":"Steinack C","year":"2023","unstructured":"Steinack C, Ernst M, Beuschlein F, et al.. Improved glucose tolerance after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis. J Cyst Fibros. 2023, 10.1016\/j.jcf.2023.01.004","journal-title":"J Cyst Fibros"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2419","article-title":"Hemoglobin A(1c) accurately predicts continuous glucose monitoring-derived average glucose in youth and young adults with cystic fibrosis","volume":"41","author":"Chan CL","year":"2018","unstructured":"Chan CL, Hope E, Thurston J, Vigers T, Pyle L, Zeitler PS, Nadeau KJ. Hemoglobin A(1c) accurately predicts continuous glucose monitoring-derived average glucose in youth and young adults with cystic fibrosis. Diabetes Care. 2018, 41:1406-1413. 10.2337\/dc17-2419","journal-title":"Diabetes Care"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines H","year":"2021","unstructured":"Gaines H, Jones KR, Lim J, Medhi NF, Chen S, Scofield RH. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. J Diabetes Complicat. 2021, 35:107845. 10.1016\/j.jdiacomp.2020.107845","journal-title":"J Diabetes Complicat"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: pancreatic islets in cystic fibrosis","volume":"241","author":"Norris AW","year":"2019","unstructured":"Norris AW, Ode KL, Merjaneh L, et al.. Survival in a bad neighborhood: pancreatic islets in cystic fibrosis. J Endocrinol. 2019, 241:R35-R50. 10.1530\/JOE-18-0468","journal-title":"J Endocrinol"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures","volume":"3","author":"Evans SR","year":"2010","unstructured":"Evans SR. Clinical trial structures. J Exp Stroke Transl Med. 2010, 3:8-18.","journal-title":"J Exp Stroke Transl Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/162438-the-effects-of-elexacaftor-tezacaftor-and-ivacaftor-eti-on-blood-glucose-in-patients-with-cystic-fibrosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:32Z","timestamp":1707509012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/162438-the-effects-of-elexacaftor-tezacaftor-and-ivacaftor-eti-on-blood-glucose-in-patients-with-cystic-fibrosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.41697","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}